Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study
Background Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical...
Saved in:
| Published in | Journal of cachexia, sarcopenia and muscle Vol. 9; no. 2; pp. 348 - 357 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Germany
John Wiley & Sons, Inc
01.04.2018
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2190-5991 2190-6009 2190-6009 |
| DOI | 10.1002/jcsm.12270 |
Cover
| Abstract | Background
Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The ‘omics’ technologies provide a global view of biological systems. We hypothesize that blood‐based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies.
Methods
This is a cross‐sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at ‘12 de Octubre’ University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC–MS), capillary electrophoresis coupled to mass spectrometry (CE–MS), and liquid chromatography coupled to mass spectrometry (LC–MS). Besides, we performed pathway‐based metabolite analyses to obtain more information on biological functions.
Results
A total of 15 subjects were included in this study, 8 cachectic and 7 non‐cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC–MS), 97% (CE–MS), 96% [LC–MS (positive mode)], and 89% [LC–MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4‐fold change (FC) compared with non‐cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O‐16:0) and lysophosphatidylcholines(20:3) sn‐1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl‐tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others.
Conclusions
These findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non‐cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. |
|---|---|
| AbstractList | Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The 'omics' technologies provide a global view of biological systems. We hypothesize that blood-based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies.BACKGROUNDCachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The 'omics' technologies provide a global view of biological systems. We hypothesize that blood-based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies.This is a cross-sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at '12 de Octubre' University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC-MS), capillary electrophoresis coupled to mass spectrometry (CE-MS), and liquid chromatography coupled to mass spectrometry (LC-MS). Besides, we performed pathway-based metabolite analyses to obtain more information on biological functions.METHODSThis is a cross-sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at '12 de Octubre' University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC-MS), capillary electrophoresis coupled to mass spectrometry (CE-MS), and liquid chromatography coupled to mass spectrometry (LC-MS). Besides, we performed pathway-based metabolite analyses to obtain more information on biological functions.A total of 15 subjects were included in this study, 8 cachectic and 7 non-cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC-MS), 97% (CE-MS), 96% [LC-MS (positive mode)], and 89% [LC-MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4-fold change (FC) compared with non-cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O-16:0) and lysophosphatidylcholines(20:3) sn-1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl-tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others.RESULTSA total of 15 subjects were included in this study, 8 cachectic and 7 non-cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC-MS), 97% (CE-MS), 96% [LC-MS (positive mode)], and 89% [LC-MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4-fold change (FC) compared with non-cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O-16:0) and lysophosphatidylcholines(20:3) sn-1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl-tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others.These findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non-cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition.CONCLUSIONSThese findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non-cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. BackgroundCachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The ‘omics’ technologies provide a global view of biological systems. We hypothesize that blood‐based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies.MethodsThis is a cross‐sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at ‘12 de Octubre’ University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC–MS), capillary electrophoresis coupled to mass spectrometry (CE–MS), and liquid chromatography coupled to mass spectrometry (LC–MS). Besides, we performed pathway‐based metabolite analyses to obtain more information on biological functions.ResultsA total of 15 subjects were included in this study, 8 cachectic and 7 non‐cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC–MS), 97% (CE–MS), 96% [LC–MS (positive mode)], and 89% [LC–MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4‐fold change (FC) compared with non‐cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O‐16:0) and lysophosphatidylcholines(20:3) sn‐1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl‐tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others.ConclusionsThese findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non‐cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. Abstract Background Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The ‘omics’ technologies provide a global view of biological systems. We hypothesize that blood‐based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies. Methods This is a cross‐sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at ‘12 de Octubre’ University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC–MS), capillary electrophoresis coupled to mass spectrometry (CE–MS), and liquid chromatography coupled to mass spectrometry (LC–MS). Besides, we performed pathway‐based metabolite analyses to obtain more information on biological functions. Results A total of 15 subjects were included in this study, 8 cachectic and 7 non‐cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC–MS), 97% (CE–MS), 96% [LC–MS (positive mode)], and 89% [LC–MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4‐fold change (FC) compared with non‐cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O‐16:0) and lysophosphatidylcholines(20:3) sn‐1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl‐tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others. Conclusions These findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non‐cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The 'omics' technologies provide a global view of biological systems. We hypothesize that blood-based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies. This is a cross-sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at '12 de Octubre' University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC-MS), capillary electrophoresis coupled to mass spectrometry (CE-MS), and liquid chromatography coupled to mass spectrometry (LC-MS). Besides, we performed pathway-based metabolite analyses to obtain more information on biological functions. A total of 15 subjects were included in this study, 8 cachectic and 7 non-cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC-MS), 97% (CE-MS), 96% [LC-MS (positive mode)], and 89% [LC-MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4-fold change (FC) compared with non-cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O-16:0) and lysophosphatidylcholines(20:3) sn-1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl-tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others. These findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non-cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. Background Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food intake and abnormal metabolism, including systemic inflammation and negative protein and energy balance. Despite its high clinical significance, defined diagnostic criteria and established therapeutic strategies are lacking. The ‘omics’ technologies provide a global view of biological systems. We hypothesize that blood‐based metabolomics might identify findings in cachectic patients that could provide clues to gain knowledge on its pathophysiology, and eventually postulate new therapeutic strategies. Methods This is a cross‐sectional observational study in two cohorts of cancer patients, with and without cachexia. Patients were consecutively recruited from routine clinical practice of a General Oncology Department at ‘12 de Octubre’ University Hospital. Selected clinical and biochemical features were collected. Blood metabolite fingerprinting was performed using three analytical platforms, gas chromatography coupled to mass spectrometry (GC–MS), capillary electrophoresis coupled to mass spectrometry (CE–MS), and liquid chromatography coupled to mass spectrometry (LC–MS). Besides, we performed pathway‐based metabolite analyses to obtain more information on biological functions. Results A total of 15 subjects were included in this study, 8 cachectic and 7 non‐cachectic patients. Metabolomic analyses were able to correctly classify their samples in 80% (GC–MS), 97% (CE–MS), 96% [LC–MS (positive mode)], and 89% [LC–MS (negative mode)] of the cases. The most prominent metabolic alteration in plasma of cachectic patients was the decrease of amino acids and derivatives [especially arginine, tryptophan, indolelactic acid, and threonine, with 0.4‐fold change (FC) compared with non‐cachectic patients], along with the reduction of glycerophospholipids [mainly lysophosphatidylcholines(O‐16:0) and lysophosphatidylcholines(20:3) sn‐1, FC = 0.1] and sphingolipids [SM(d30:0), FC = 0.5]. The metabolite with the highest increase was cortisol (FC = 1.6). Such alterations suggest a role of the following metabolic pathways in the pathophysiology of cancer cachexia: arginine and proline metabolism; alanine, aspartate, and glutamate metabolism; phenylalanine metabolism; lysine degradation; aminoacyl‐tRNA biosynthesis; fatty acid elongation in mitochondria; tricarboxylic acids cycle; among others. Conclusions These findings suggest that plasma amino acids and lipids profiling has great potential to find the mechanisms involved in the pathogenesis of cachexia. Metabolic profiling of plasma from cancer patients show differences between cachexia and non‐cachexia in amino acids and lipids that might be related to mechanisms involved in its pathophysiology. A better understanding of these mechanisms might identify novel therapeutic approaches to palliate this unmet medical condition. |
| Author | Rupérez, Francisco Javier Díaz‐García, Carmen Vanesa Parrilla‐Rubio, Lucía Cala, Mónica Patricia García, Antonia Barbas, Coral Prieto‐García, Elena Pernaut, Cristina Adeva, Jorge Riesco, María Carmen González‐Riano, Carolina Agulló‐Ortuño, María Teresa Lopez‐Martin, Jose Antonio |
| AuthorAffiliation | 2 Grupo de Investigación en Química Analítica y Bioanalítica (GABIO), Department of Chemistry, Faculty of Sciences Universidad de los Andes Cra. 1 No. 18a‐10 111710 Bogotá Colombia 4 Medical Oncology Department Hospital Universitario 12 de Octubre Av de Córdoba s/n 28041 Madrid Spain 1 Centre for Metabolomic and Bioanalysis (CEMBIO), Facultad de Farmacia Universidad San Pablo CEU Urbanización Montepríncipe, M‐501 km 0 28660 Boadilla del Monte, Madrid Spain 3 Clinical & Translational Cancer Research Group Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12) Av Córdoba s/n 28041 Madrid Spain |
| AuthorAffiliation_xml | – name: 2 Grupo de Investigación en Química Analítica y Bioanalítica (GABIO), Department of Chemistry, Faculty of Sciences Universidad de los Andes Cra. 1 No. 18a‐10 111710 Bogotá Colombia – name: 3 Clinical & Translational Cancer Research Group Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12) Av Córdoba s/n 28041 Madrid Spain – name: 1 Centre for Metabolomic and Bioanalysis (CEMBIO), Facultad de Farmacia Universidad San Pablo CEU Urbanización Montepríncipe, M‐501 km 0 28660 Boadilla del Monte, Madrid Spain – name: 4 Medical Oncology Department Hospital Universitario 12 de Octubre Av de Córdoba s/n 28041 Madrid Spain |
| Author_xml | – sequence: 1 givenname: Mónica Patricia orcidid: 0000-0002-8198-726X surname: Cala fullname: Cala, Mónica Patricia organization: Universidad de los Andes – sequence: 2 givenname: María Teresa orcidid: 0000-0002-7617-6681 surname: Agulló‐Ortuño fullname: Agulló‐Ortuño, María Teresa organization: Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12) – sequence: 3 givenname: Elena orcidid: 0000-0003-1159-0942 surname: Prieto‐García fullname: Prieto‐García, Elena organization: Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12) – sequence: 4 givenname: Carolina surname: González‐Riano fullname: González‐Riano, Carolina organization: Universidad San Pablo CEU – sequence: 5 givenname: Lucía surname: Parrilla‐Rubio fullname: Parrilla‐Rubio, Lucía organization: Hospital Universitario 12 de Octubre – sequence: 6 givenname: Coral surname: Barbas fullname: Barbas, Coral organization: Universidad San Pablo CEU – sequence: 7 givenname: Carmen Vanesa surname: Díaz‐García fullname: Díaz‐García, Carmen Vanesa organization: Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12) – sequence: 8 givenname: Antonia orcidid: 0000-0002-1521-8489 surname: García fullname: García, Antonia organization: Universidad San Pablo CEU – sequence: 9 givenname: Cristina surname: Pernaut fullname: Pernaut, Cristina organization: Hospital Universitario 12 de Octubre – sequence: 10 givenname: Jorge surname: Adeva fullname: Adeva, Jorge organization: Hospital Universitario 12 de Octubre – sequence: 11 givenname: María Carmen surname: Riesco fullname: Riesco, María Carmen organization: Hospital Universitario 12 de Octubre – sequence: 12 givenname: Francisco Javier surname: Rupérez fullname: Rupérez, Francisco Javier organization: Universidad San Pablo CEU – sequence: 13 givenname: Jose Antonio orcidid: 0000-0001-7530-3207 surname: Lopez‐Martin fullname: Lopez‐Martin, Jose Antonio email: jalopezmartin@gmail.com organization: Hospital Universitario 12 de Octubre |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29464940$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU1v1DAQhiNUREvphR-AInFBRVvGTmLHHJDQio-iVhyAszVxnK1Xjp3aSdv997ibbUUrVF9mNH7m1cw7L7M9553OstcETggA_bBWsT8hlHJ4lh1QImDBAMTeLq-EIPvZUYxrSK9khFXwItunomSlKOEg0-eTHc1gcex86POUxB7zzriVDkMwbkxZblyu0CkdUlAX-sbgxxzzwVg_5r6JOlzhaLxDm6Nr8zGgi_auEsep3bzKnndooz7axcPsz9cvv5ffF2c_v50uP58tVFVSWNQcQTClVFeJtlOKA6etEqSltSbYCEUpq7XoeFsw0oiGCVImnDek4oBVWxxmp7Nu63Et0_w9ho30aOS24MNKYhiNslryJNsUTcmB0LJjVGBNEdqmYo0iDMqk9X7WmtyAm2u09l6QgLz1Xt56L7feJ_rTTA9T0-tWaZdssA9GePjjzIVc-StZ1VyIiieBdzuB4C8nHUfZm6i0tei0n6KkAJwQVlKW0LeP0LWfQjI7UQUVvChqKBL15t-J7ke5u30CjmdABR9j0N3T-8EjWJlxe-O0jbH_byFzy7WxevOEuPyx_HU-9_wFAxzheQ |
| CitedBy_id | crossref_primary_10_1016_j_exger_2022_111924 crossref_primary_10_1016_j_jneuroim_2023_578033 crossref_primary_10_1038_s41598_022_04994_6 crossref_primary_10_3389_fonc_2024_1286896 crossref_primary_10_1002_rco2_68 crossref_primary_10_1007_s11356_022_23539_y crossref_primary_10_1002_jcsm_12939 crossref_primary_10_1002_jcsm_12817 crossref_primary_10_1172_jci_insight_136687 crossref_primary_10_1136_ijgc_2020_001862 crossref_primary_10_1016_j_jstrokecerebrovasdis_2018_12_035 crossref_primary_10_1152_ajpendo_00526_2018 crossref_primary_10_1016_j_chroma_2020_461758 crossref_primary_10_1038_s41598_022_19576_9 crossref_primary_10_1007_s11332_022_01008_w crossref_primary_10_1016_j_lfs_2023_122172 crossref_primary_10_1007_s12020_021_02858_z crossref_primary_10_1038_s42255_024_01167_9 crossref_primary_10_1038_s41598_020_63306_y crossref_primary_10_3389_fcell_2021_720096 crossref_primary_10_1016_j_jep_2022_115222 crossref_primary_10_1016_j_metabol_2024_156034 crossref_primary_10_3390_cancers11091222 crossref_primary_10_1007_s00520_024_08350_4 crossref_primary_10_1097_j_pbj_0000000000000123 crossref_primary_10_3390_metabo12060519 crossref_primary_10_1016_j_microc_2023_108452 crossref_primary_10_1021_acs_analchem_8b04715 crossref_primary_10_1016_j_trac_2023_117049 crossref_primary_10_3389_fphar_2022_947095 crossref_primary_10_1016_j_scitotenv_2022_158722 crossref_primary_10_1186_s13395_018_0188_4 crossref_primary_10_2139_ssrn_4140142 crossref_primary_10_34175_jno202001001 crossref_primary_10_1021_acs_jproteome_9b00088 crossref_primary_10_3390_cancers16132364 crossref_primary_10_1002_1878_0261_13590 crossref_primary_10_3389_fonc_2021_683289 crossref_primary_10_1002_jcsm_12518 crossref_primary_10_1016_j_talanta_2022_123452 crossref_primary_10_1186_s12885_024_12964_6 crossref_primary_10_3390_cancers14071814 crossref_primary_10_1002_elps_201800323 crossref_primary_10_3390_ijms222413575 crossref_primary_10_1002_prca_202300035 crossref_primary_10_1186_s13049_019_0631_5 crossref_primary_10_1002_elps_201800331 crossref_primary_10_3390_nu12072106 crossref_primary_10_1016_j_aca_2021_338577 crossref_primary_10_1016_j_bcp_2021_114503 crossref_primary_10_1016_j_jpba_2020_113509 crossref_primary_10_3390_cancers11101594 crossref_primary_10_1002_jcsm_12626 crossref_primary_10_3389_fmolb_2022_789889 crossref_primary_10_1021_acs_analchem_9b04553 crossref_primary_10_1371_journal_pone_0230844 crossref_primary_10_1016_j_jchromb_2019_121819 crossref_primary_10_3390_ijms241613005 crossref_primary_10_1242_dmm_048249 crossref_primary_10_1038_s41420_024_02271_1 crossref_primary_10_3389_fphys_2024_1465946 crossref_primary_10_3390_cancers11101541 crossref_primary_10_4236_jct_2023_141004 crossref_primary_10_1002_jcsm_13474 |
| Cites_doi | 10.1093/ajcn/71.2.583 10.1210/en.2004-0037 10.3389/fbioe.2015.00022 10.3389/fphys.2015.00012 10.1016/j.mehy.2006.04.048 10.1007/s00520-010-1075-7 10.3945/ajcn.116.140434 10.1002/1097-0142(197401)33:1<66::AID-CNCR2820330113>3.0.CO;2-0 10.3748/wjg.v12.i28.4541 10.4161/cc.9.19.13302 10.2174/1568026614666141215124956 10.1093/ajcn/83.4.735 10.1016/j.clnu.2012.06.012 10.1039/c2mb25194a 10.1016/j.bbalip.2012.10.008 10.1186/s13073-016-0289-9 10.1016/j.nut.2011.11.026 10.1155/2015/820934 10.1093/annonc/mdu085 10.1016/j.clnu.2011.08.008 10.1007/s13539-011-0051-5 10.1007/s40520-015-0353-0 10.1007/s11745-999-332-5 10.1096/fasebj.29.1_supplement.367.1 10.1038/nrclinonc.2012.209 10.1093/nar/gkv380 10.1007/s00520-013-1881-9 10.1016/j.clnu.2008.06.013 10.1007/978-3-662-22346-8_9 10.1007/s13539-014-0164-8 10.1007/s11739-010-0426-1 10.1007/s11306-010-0232-9 10.1038/nrc3829 10.1002/jcsm.12089 10.4331/wjbc.v3.i8.167 10.1590/1806-9282.60.01.017 10.1207/S15327914NC352_16 10.1053/meta.2000.6740 10.1074/mcp.M116.063313 10.1016/j.lungcan.2011.05.009 10.1186/s12885-016-2121-8 10.1097/SPC.0b013e328359b668 10.4155/cli.14.56 10.1016/S1470-2045(10)70218-7 10.1089/ars.2011.3940 10.3892/mco.2017.1261 10.1097/SPC.0b013e328359b695 10.1158/1078-0432.CCR-16-0495 10.1016/j.jchromb.2008.05.048 10.1016/j.semcdb.2015.12.022 10.1152/physrev.00016.2008 10.1093/bioinformatics/btq418 10.1007/s00535-013-0787-0 10.1200/JCO.2014.56.1894 10.1007/s11306-008-0113-7 10.1007/s13539-010-0002-6 10.1016/j.biochi.2012.07.009 10.3109/10408369309084669 10.1371/journal.pone.0127299 10.1016/j.cmet.2012.06.011 10.1093/jnci/djr556 10.1371/journal.pone.0113259 10.1002/ijc.29950 10.4251/wjgo.v7.i4.17 10.1016/j.autneu.2011.09.006 10.1186/1471-2407-13-77 |
| ContentType | Journal Article |
| Copyright | 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders – notice: 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. – notice: 2018. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1002/jcsm.12270 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 6 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Multiplatform plasma fingerprinting in cancer cachexia |
| EISSN | 2190-6009 |
| EndPage | 357 |
| ExternalDocumentID | oai_doaj_org_article_791db3b470124f629a82a0db56bc1604 10.1002/jcsm.12270 PMC5879957 29464940 10_1002_jcsm_12270 JCSM12270 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: European Regional Development Fund funderid: grant number PI10/02072 – fundername: European Regional Development Fund grantid: grant number PI10/02072 |
| GroupedDBID | --- 0R~ 1OC 24P 2VQ 4.4 40G 53G 5VS 7X7 8FI 8FJ AAHHS AAKDD AAZKR ABUWG ACCFJ ACCMX ACXQS ADBBV ADINQ ADKYN ADPDF ADRAZ ADZMN ADZOD AEEZP AENEX AEQDE AFKRA AHBYD AHSBF AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AMKLP AOIJS AVUZU AZFZN BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU DIK EBS EJD EMOBN FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR INH ITC KQ8 M48 M~E O9- OK1 OVD OVEED PIMPY PQQKQ PROAC RPM RSV SMD SOJ U2A UKHRP WIN ZOVNA AAFWJ AAMMB AAYXX AEFGJ AFPKN AGXDD AIDQK AIDYY CITATION PHGZM PHGZT PUEGO CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c5420-87a096cccf59dfcc7072dc91d28e1ab9c2268e9f7d361b9b69146cc7b1570a5d3 |
| IEDL.DBID | M48 |
| ISSN | 2190-5991 2190-6009 |
| IngestDate | Tue Oct 14 18:56:28 EDT 2025 Sun Oct 26 04:15:44 EDT 2025 Tue Sep 30 16:52:23 EDT 2025 Thu Oct 02 05:46:56 EDT 2025 Tue Oct 07 07:13:32 EDT 2025 Thu Apr 03 07:01:53 EDT 2025 Wed Oct 01 03:24:43 EDT 2025 Thu Apr 24 22:59:03 EDT 2025 Wed Jan 22 17:08:45 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Biomarkers Metabolomics Cachexia Cancer |
| Language | English |
| License | Attribution-NonCommercial 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. cc-by |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5420-87a096cccf59dfcc7072dc91d28e1ab9c2268e9f7d361b9b69146cc7b1570a5d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1521-8489 0000-0003-1159-0942 0000-0001-7530-3207 0000-0002-8198-726X 0000-0002-7617-6681 |
| OpenAccessLink | https://doaj.org/article/791db3b470124f629a82a0db56bc1604 |
| PMID | 29464940 |
| PQID | 2329733803 |
| PQPubID | 4370305 |
| PageCount | 10 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_791db3b470124f629a82a0db56bc1604 unpaywall_primary_10_1002_jcsm_12270 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5879957 proquest_miscellaneous_2007116426 proquest_journals_2329733803 pubmed_primary_29464940 crossref_primary_10_1002_jcsm_12270 crossref_citationtrail_10_1002_jcsm_12270 wiley_primary_10_1002_jcsm_12270_JCSM12270 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | April 2018 |
| PublicationDateYYYYMMDD | 2018-04-01 |
| PublicationDate_xml | – month: 04 year: 2018 text: April 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | Germany |
| PublicationPlace_xml | – name: Germany – name: Heidelberg – name: Hoboken |
| PublicationTitle | Journal of cachexia, sarcopenia and muscle |
| PublicationTitleAlternate | J Cachexia Sarcopenia Muscle |
| PublicationYear | 2018 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2009; 89 1979; 39 2017; 7 2012; 166 2000; 49 2013; 21 2015; 33 2014; 25 2011; 12 2012; 16 2011; 15 2008; 4 2014; 60 2017; 31 2014; 5 2014; 4 2010; 26 2010; 1 2006; 67 2013; 10 2013; 13 2013; 95 2008; 27 2015; 43 1993; 30 2014; 14 2012; 28 2014; 9 2008; 871 2012; 20 2010; 9 2004; 145 2013; 48 2015; 6 1974; 33 2013; 1831 2015; 3 2006; 12 2015; 10 2016; 54 2011; 74 2000; 71 2012; 104 2016; 16 2011; 6 2015; 7 2012; 31 2011; 7 2016; 5 2012; 3 2006; 83 2015; 29 2017; 16 2015; 2015 1999; 35 1999; 34 2017 2016; 138 2012; 6 2016; 28 2016; 8 2017; 105 1996; XV 2012; 8 2016; 22 e_1_2_7_5_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_60_1 e_1_2_7_17_1 e_1_2_7_62_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_64_1 e_1_2_7_13_1 e_1_2_7_43_1 e_1_2_7_66_1 e_1_2_7_11_1 e_1_2_7_45_1 e_1_2_7_68_1 e_1_2_7_47_1 e_1_2_7_49_1 e_1_2_7_28_1 e_1_2_7_50_1 e_1_2_7_25_1 e_1_2_7_31_1 e_1_2_7_52_1 e_1_2_7_23_1 e_1_2_7_33_1 e_1_2_7_54_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_56_1 e_1_2_7_37_1 e_1_2_7_39_1 e_1_2_7_6_1 e_1_2_7_4_1 e_1_2_7_8_1 Arthur ST (e_1_2_7_71_1) 2015; 6 e_1_2_7_18_1 e_1_2_7_16_1 e_1_2_7_61_1 e_1_2_7_2_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_63_1 Jouinot A (e_1_2_7_12_1) 2017 e_1_2_7_44_1 e_1_2_7_65_1 e_1_2_7_10_1 e_1_2_7_46_1 e_1_2_7_67_1 e_1_2_7_48_1 e_1_2_7_69_1 e_1_2_7_27_1 e_1_2_7_29_1 Dev R (e_1_2_7_51_1) 2017; 31 e_1_2_7_72_1 e_1_2_7_70_1 e_1_2_7_30_1 e_1_2_7_53_1 e_1_2_7_24_1 Wishart D. (e_1_2_7_26_1) 2015; 29 e_1_2_7_32_1 e_1_2_7_55_1 e_1_2_7_22_1 e_1_2_7_34_1 e_1_2_7_57_1 Waterhouse C (e_1_2_7_58_1) 1979; 39 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_59_1 e_1_2_7_38_1 Porporato PE (e_1_2_7_40_1) 2016; 5 |
| References_xml | – volume: 89 start-page: 381 year: 2009 end-page: 410 article-title: Mechanisms of cancer cachexia publication-title: Physiol Rev – volume: 71 start-page: 583 year: 2000 end-page: 589 article-title: Weight loss and elevated gluconeogenesis from alanine in lung cancer patients publication-title: Am J Clin Nutr – volume: 33 start-page: 90 year: 2015 end-page: 99 article-title: Diagnostic criteria for the classification of cancer‐associated weight loss. Diagnostic criteria for the classification of cancer‐associated weight loss publication-title: J Clin Oncol – volume: 166 start-page: 93 year: 2012 end-page: 95 article-title: Exploring autonomic nervous system dysfunction in patients with cancer cachexia: a pilot study publication-title: Auton Neurosci – volume: 12 start-page: 4541 year: 2006 end-page: 4545 article-title: Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia publication-title: World J Gastroenterol – volume: 13 start-page: 77 year: 2013 article-title: The significance and robustness of a plasma free amino acid (PFAA) profile‐based multiplex function for detecting lung cancer publication-title: BMC Cancer – volume: 29 year: 2015 article-title: Metabolism, Metabolomics and Cancer publication-title: FASEB J – volume: 7 start-page: 17 year: 2015 end-page: 29 article-title: Cancer cachexia, mechanism and treatment publication-title: World J Gastrointest Oncol – volume: 15 start-page: 2501 year: 2011 end-page: 2517 article-title: Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle publication-title: Antioxid Redox Signal – volume: 33 start-page: 66 year: 1974 end-page: 71 article-title: Lactate metabolism in patients with cancer publication-title: Cancer – volume: 105 start-page: 1139 year: 2017 end-page: 1147 article-title: Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy publication-title: Am J Clin Nutr – volume: 8 start-page: 34 year: 2016 article-title: Novel personalized pathway‐based metabolomics models reveal key metabolic pathways for breast cancer diagnosis publication-title: Genome Med – volume: 35 start-page: 202 year: 1999 end-page: 206 article-title: Glucocorticoid blockade does not abrogate tumor‐induced cachexia publication-title: Nutr Cancer – volume: 28 start-page: 17 year: 2016 end-page: 23 article-title: Recent advances in the role of cortisol and metabolic syndrome in age‐related degenerative diseases publication-title: Aging Clin Exp Res – volume: 871 start-page: 299 year: 2008 end-page: 305 article-title: Evaluation of the repeatability of ultra‐performance liquid chromatography‐TOF‐MS for global metabolic profiling of human urine samples publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 48 start-page: 574 year: 2013 end-page: 594 article-title: Cancer cachexia‐‐pathophysiology and management publication-title: J Gastroenterol – volume: 1 start-page: 1 issue: 1 year: 2010 end-page: 5 article-title: Cachexia as a major underestimated and unmet medical need: facts and numbers publication-title: J Cachexia Sarcopenia Muscle – volume: 26 start-page: 2342 year: 2010 end-page: 2344 article-title: MetPA: a web‐based metabolomics tool for pathway analysis and visualization publication-title: Bioinformatics – volume: 49 start-page: 931 year: 2000 end-page: 936 article-title: Lipolysis and lipid oxidation in weight‐losing cancer patients and healthy subjects publication-title: Metabolism – volume: 31 start-page: 74 year: 2012 end-page: 77 article-title: Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer publication-title: Clin Nutr – volume: 74 start-page: 516 year: 2011 end-page: 520 article-title: Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis publication-title: Lung Cancer – volume: 6 start-page: 315 year: 2015 end-page: 316 article-title: Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2015 publication-title: J Cachexia Sarcopenia Muscle – volume: 27 start-page: 793 year: 2008 end-page: 799 article-title: Cachexia: a new definition publication-title: Clin Nutr – volume: 34 start-page: 17 year: 1999 end-page: 21 article-title: Abnormal serum lysophospholipids in multiple myeloma patients publication-title: Lipids – volume: 5 start-page: 261 year: 2014 end-page: 263 article-title: Prevalence, incidence and clinical impact of cachexia: facts and numbers‐update 2014 publication-title: J Cachexia Sarcopenia Muscle – volume: 95 start-page: 27 year: 2013 end-page: 32 article-title: Implication of liver cardiolipins in mitochondrial energy metabolism disorder in cancer cachexia publication-title: Biochimie – volume: 3 start-page: 22 year: 2015 article-title: Open‐access metabolomics databases for natural product research: present capabilities and future potential publication-title: Front Bioeng Biotechnol – volume: 16 start-page: 75 year: 2016 article-title: Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia‐‐can findings from animal models be translated to humans? publication-title: BMC Cancer – volume: XV start-page: 123 year: 1996 end-page: 132 – volume: 16 start-page: 153 year: 2012 end-page: 166 article-title: Cancer cachexia: mediators, signaling, and metabolic pathways publication-title: Cell Metab – volume: 1831 start-page: 663 year: 2013 end-page: 674 article-title: Anticancer mechanisms and clinical application of alkylphospholipids publication-title: Biochim Biophys Acta – volume: 20 start-page: 301 year: 2012 end-page: 309 article-title: Weight loss in cancer patients: a plea for a better awareness of the issue publication-title: Support Care Cancer – volume: 60 start-page: 84 year: 2014 end-page: 92 article-title: Cortisol: the villain in metabolic syndrome? publication-title: Revista da Associacao Rev Assoc Med Bras – volume: 8 start-page: 3125 year: 2012 end-page: 3133 article-title: Targeted metabolomics identifies perturbations in amino acid metabolism that sub‐classify patients with COPD publication-title: Mol BioSyst – volume: 2015 start-page: 820934 year: 2015 article-title: Potential Biomarkers of Fat Loss as a Feature of Cancer Cachexia publication-title: Mediat Inflamm – volume: 30 start-page: 223 year: 1993 end-page: 272 article-title: Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions publication-title: Crit Rev Clin Lab Sci – volume: 3 start-page: 5 year: 2012 end-page: 11 article-title: The role of insulin resistance in the development of muscle wasting during cancer cachexia publication-title: J Cachexia Sarcopenia Muscle – volume: 10 start-page: e0127299 year: 2015 article-title: GC‐MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort publication-title: PLoS One – volume: 22 start-page: 3999 year: 2016 end-page: 4004 article-title: Molecular Pathways: Cachexia Signaling‐A Targeted Approach to Cancer Treatment publication-title: Clin Cancer Res – volume: 28 start-page: 851 year: 2012 end-page: 855 article-title: Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia publication-title: Nutrition – volume: 12 start-page: 489 year: 2011 end-page: 495 article-title: Definition and classification of cancer cachexia: an international consensus publication-title: Lancet Oncol – volume: 31 start-page: 577 year: 2012 end-page: 582 article-title: The 2011 ESPEN Arvid Wretlind lecture: cancer cachexia: the potential impact of translational research on patient‐focused outcomes publication-title: Clin Nutr – volume: 104 start-page: 371 year: 2012 end-page: 385 article-title: Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta‐analysis publication-title: J Natl Cancer Inst – volume: 138 start-page: 2785 year: 2016 end-page: 2794 article-title: Adrenocortical tumors and insulin resistance: What is the first step? publication-title: Int J Cancer – volume: 14 start-page: 754 year: 2014 end-page: 762 article-title: Cancer cachexia: understanding the molecular basis publication-title: Nat Rev Cancer – volume: 9 start-page: e113259 year: 2014 article-title: Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra‐Day Variation in Patients with Advanced Pancreatic Cancer publication-title: PLoS One – volume: 3 start-page: 167 year: 2012 end-page: 174 article-title: Dysregulated lipid metabolism in cancer publication-title: World J Biol Chem – volume: 6 start-page: 12 year: 2015 article-title: The regulation of muscle mass by endogenous glucocorticoids publication-title: Front Physiol – volume: 7 start-page: 121 year: 2017 end-page: 124 article-title: Modified glasgow prognostic score in patients with small‐cell lung cancer publication-title: Mol Clin Oncol – volume: 39 start-page: 1968 year: 1979 end-page: 1972 article-title: Gluconeogenesis from alanine in patients with progressive malignant disease publication-title: Cancer Res – volume: 6 start-page: 105 year: 2011 end-page: 112 article-title: The “parallel pathway”: a novel nutritional and metabolic approach to cancer patients publication-title: Intern Emerg Med – volume: 6 start-page: 424 year: 2012 end-page: 431 article-title: Evidence base for multimodal therapy in cachexia publication-title: Curr Opin Support Palliat Care – volume: 5 year: 2016 article-title: Understanding cachexia as a cancer metabolism syndrome publication-title: Oncogene – volume: 31 start-page: 23 year: 2017 end-page: 32 article-title: The Evolving Approach to Management of Cancer Cachexia publication-title: Oncology – volume: 9 start-page: 3884 year: 2010 end-page: 3886 article-title: Glutaminolysis: supplying carbon or nitrogen or both for cancer cells? publication-title: Cell Cycle – volume: 10 start-page: 90 year: 2013 end-page: 99 article-title: Understanding the mechanisms and treatment options in cancer cachexia publication-title: Nat Rev Clin Oncol – volume: 25 start-page: 1492 year: 2014 end-page: 1499 article-title: Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force publication-title: Ann Oncol – volume: 4 start-page: 601 year: 2014 end-page: 604 article-title: B.H. ON. Cancer cachexia: an unmet need in cancer treatment publication-title: Clin Investig – volume: 6 start-page: 315 year: 2015 end-page: 316 article-title: Cachexia among US cancer patients publication-title: J Cachexia Sarcopenia Muscle – volume: 6 start-page: 446 year: 2012 end-page: 450 article-title: Translational implications of novel findings in cancer cachexia: the use of metabolomics and the potential of cardiac malfunction publication-title: Curr Opin Support Palliat Care – volume: 21 start-page: 2625 year: 2013 end-page: 2636 article-title: A systematic review of health‐related quality of life instruments in patients with cancer cachexia publication-title: Support Care Cancer – volume: 16 start-page: 86 year: 2017 end-page: 99 article-title: Multi‐omics Analysis of Serum Samples Demonstrates Reprogramming of Organ Functions Via Systemic Calcium Mobilization and Platelet Activation in Metastatic Melanoma publication-title: Mol Cell Proteomics – year: 2017 article-title: Resting energy expenditure in the risk assessment of anticancer treatments publication-title: Clin Nutr – volume: 54 start-page: 92 year: 2016 end-page: 103 article-title: Omics/systems biology and cancer cachexia publication-title: Semin Cell Dev Biol – volume: 14 start-page: 2627 year: 2014 end-page: 2636 article-title: Metabolomics as a tool for drug discovery and personalised medicine publication-title: A review Curr Top Med Chem – volume: 7 start-page: 25 year: 2011 end-page: 34 article-title: Learning to predict cancer‐associated skeletal muscle wasting from 1H‐NMR profiles of urinary metabolites publication-title: Metabolomics – volume: 83 start-page: 735 year: 2006 end-page: 743 article-title: Cachexia: pathophysiology and clinical relevance publication-title: Am J Clin Nutr – volume: 145 start-page: 2633 year: 2004 end-page: 2638 article-title: Minireview: glucocorticoids‐‐food intake, abdominal obesity, and wealthy nations in 2004 publication-title: Endocrinology – volume: 67 start-page: 1213 year: 2006 end-page: 1222 article-title: Cancer cachexia demonstrates the energetic impact of gluconeogenesis in human metabolism publication-title: Med Hypotheses – volume: 4 start-page: 216 year: 2008 article-title: Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations publication-title: Metabolomics – volume: 43 start-page: W251 year: 2015 end-page: W257 article-title: MetaboAnalyst 3.0‐‐making metabolomics more meaningful publication-title: Nucleic Acids Res – ident: e_1_2_7_59_1 doi: 10.1093/ajcn/71.2.583 – ident: e_1_2_7_50_1 doi: 10.1210/en.2004-0037 – ident: e_1_2_7_70_1 doi: 10.3389/fbioe.2015.00022 – ident: e_1_2_7_47_1 doi: 10.3389/fphys.2015.00012 – ident: e_1_2_7_60_1 doi: 10.1016/j.mehy.2006.04.048 – ident: e_1_2_7_10_1 doi: 10.1007/s00520-010-1075-7 – ident: e_1_2_7_11_1 doi: 10.3945/ajcn.116.140434 – ident: e_1_2_7_57_1 doi: 10.1002/1097-0142(197401)33:1<66::AID-CNCR2820330113>3.0.CO;2-0 – ident: e_1_2_7_37_1 doi: 10.3748/wjg.v12.i28.4541 – ident: e_1_2_7_66_1 doi: 10.4161/cc.9.19.13302 – ident: e_1_2_7_24_1 doi: 10.2174/1568026614666141215124956 – ident: e_1_2_7_42_1 doi: 10.1093/ajcn/83.4.735 – ident: e_1_2_7_9_1 doi: 10.1016/j.clnu.2012.06.012 – ident: e_1_2_7_52_1 doi: 10.1039/c2mb25194a – ident: e_1_2_7_65_1 doi: 10.1016/j.bbalip.2012.10.008 – ident: e_1_2_7_25_1 doi: 10.1186/s13073-016-0289-9 – ident: e_1_2_7_34_1 doi: 10.1016/j.nut.2011.11.026 – ident: e_1_2_7_36_1 doi: 10.1155/2015/820934 – ident: e_1_2_7_20_1 doi: 10.1093/annonc/mdu085 – volume: 39 start-page: 1968 year: 1979 ident: e_1_2_7_58_1 article-title: Gluconeogenesis from alanine in patients with progressive malignant disease publication-title: Cancer Res – ident: e_1_2_7_68_1 doi: 10.1016/j.clnu.2011.08.008 – ident: e_1_2_7_49_1 doi: 10.1007/s13539-011-0051-5 – ident: e_1_2_7_46_1 doi: 10.1007/s40520-015-0353-0 – ident: e_1_2_7_63_1 doi: 10.1007/s11745-999-332-5 – volume: 6 start-page: 315 year: 2015 ident: e_1_2_7_71_1 article-title: Cachexia among US cancer patients publication-title: J Cachexia Sarcopenia Muscle – volume: 29 year: 2015 ident: e_1_2_7_26_1 article-title: Metabolism, Metabolomics and Cancer publication-title: FASEB J doi: 10.1096/fasebj.29.1_supplement.367.1 – ident: e_1_2_7_13_1 doi: 10.1038/nrclinonc.2012.209 – ident: e_1_2_7_33_1 doi: 10.1093/nar/gkv380 – ident: e_1_2_7_6_1 doi: 10.1007/s00520-013-1881-9 – year: 2017 ident: e_1_2_7_12_1 article-title: Resting energy expenditure in the risk assessment of anticancer treatments publication-title: Clin Nutr – ident: e_1_2_7_2_1 doi: 10.1016/j.clnu.2008.06.013 – ident: e_1_2_7_55_1 doi: 10.1007/978-3-662-22346-8_9 – ident: e_1_2_7_4_1 doi: 10.1007/s13539-014-0164-8 – ident: e_1_2_7_69_1 doi: 10.1007/s11739-010-0426-1 – ident: e_1_2_7_29_1 doi: 10.1007/s11306-010-0232-9 – ident: e_1_2_7_5_1 doi: 10.1038/nrc3829 – ident: e_1_2_7_72_1 doi: 10.1002/jcsm.12089 – ident: e_1_2_7_62_1 doi: 10.4331/wjbc.v3.i8.167 – ident: e_1_2_7_48_1 doi: 10.1590/1806-9282.60.01.017 – ident: e_1_2_7_44_1 doi: 10.1207/S15327914NC352_16 – ident: e_1_2_7_35_1 doi: 10.1053/meta.2000.6740 – ident: e_1_2_7_64_1 doi: 10.1074/mcp.M116.063313 – ident: e_1_2_7_38_1 doi: 10.1016/j.lungcan.2011.05.009 – ident: e_1_2_7_39_1 doi: 10.1186/s12885-016-2121-8 – ident: e_1_2_7_67_1 doi: 10.1097/SPC.0b013e328359b668 – ident: e_1_2_7_23_1 doi: 10.4155/cli.14.56 – ident: e_1_2_7_3_1 doi: 10.1016/S1470-2045(10)70218-7 – ident: e_1_2_7_43_1 doi: 10.1089/ars.2011.3940 – ident: e_1_2_7_8_1 doi: 10.3892/mco.2017.1261 – ident: e_1_2_7_27_1 doi: 10.1097/SPC.0b013e328359b695 – ident: e_1_2_7_41_1 doi: 10.1158/1078-0432.CCR-16-0495 – ident: e_1_2_7_31_1 doi: 10.1016/j.jchromb.2008.05.048 – ident: e_1_2_7_19_1 doi: 10.1016/j.semcdb.2015.12.022 – volume: 5 year: 2016 ident: e_1_2_7_40_1 article-title: Understanding cachexia as a cancer metabolism syndrome publication-title: Oncogene – ident: e_1_2_7_7_1 doi: 10.1152/physrev.00016.2008 – ident: e_1_2_7_32_1 doi: 10.1093/bioinformatics/btq418 – ident: e_1_2_7_14_1 doi: 10.1007/s00535-013-0787-0 – ident: e_1_2_7_16_1 doi: 10.1200/JCO.2014.56.1894 – ident: e_1_2_7_28_1 doi: 10.1007/s11306-008-0113-7 – ident: e_1_2_7_22_1 doi: 10.1007/s13539-010-0002-6 – ident: e_1_2_7_17_1 doi: 10.1016/j.biochi.2012.07.009 – ident: e_1_2_7_54_1 doi: 10.3109/10408369309084669 – ident: e_1_2_7_53_1 doi: 10.1371/journal.pone.0127299 – ident: e_1_2_7_15_1 doi: 10.1016/j.cmet.2012.06.011 – ident: e_1_2_7_21_1 doi: 10.1093/jnci/djr556 – ident: e_1_2_7_30_1 doi: 10.1371/journal.pone.0113259 – ident: e_1_2_7_61_1 doi: 10.1002/ijc.29950 – volume: 31 start-page: 23 year: 2017 ident: e_1_2_7_51_1 article-title: The Evolving Approach to Management of Cancer Cachexia publication-title: Oncology – ident: e_1_2_7_18_1 doi: 10.4251/wjgo.v7.i4.17 – ident: e_1_2_7_45_1 doi: 10.1016/j.autneu.2011.09.006 – ident: e_1_2_7_56_1 doi: 10.1186/1471-2407-13-77 |
| SSID | ssj0000461650 |
| Score | 2.4166417 |
| Snippet | Background
Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of... Cachexia is a metabolic syndrome that affects up to 50-80% of cancer patients. The pathophysiology is characterized by a variable combination of reduced food... BackgroundCachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable combination of... Abstract Background Cachexia is a metabolic syndrome that affects up to 50–80% of cancer patients. The pathophysiology is characterized by a variable... |
| SourceID | doaj unpaywall pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 348 |
| SubjectTerms | Adult Aged Aged, 80 and over Anorexia Biomarkers Cachexia Cachexia - diagnosis Cachexia - pathology Cancer Case-Control Studies Chromatography Cross-Sectional Studies Data analysis Energy Exports Female Genomes Humans Male Mass spectrometry Metabolism Metabolites Metabolomics Metabolomics - methods Middle Aged Neoplasms - complications Neoplasms - pathology NMR Nuclear magnetic resonance Original Patients Pilot Projects Principal components analysis Quantitative analysis Scientific imaging Software |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD8AFlXdoQUb0AtJSx_GTG1RUVaXlApV6s2zHEYvS7KqbVdt_37GdjXZFVS6cYiUTxZkZ2984k28QOnC-qRpn3YQ4S-LWjZtogPnQCiwIQbVMf_FPf4iTM3Z6zs83Sn3FnLBMD5wVdyh1WbvKMQkzKWvgZquoJbXjwvlSZCZQovRGMJXmYCZKkcqz0vivNAcUNHKT0sM_fnnxuaQ0VijeWI0Saf9dSPPvhMlHq25hb65s226D2rQqHe-iJwOcxF_zazxFD0L3DD2cDh_Mn6MwzQmDto_gFENjeWFxk_by4pZeTHrGsw77aPxLOIANr2f2C7Z4MWvnPZ67cdsWnmO7GvdxdWvXZxI97Qt0dvz919HJZKisMPGcQbyopIXQxXvfcF033ksiae1B01SF0jrtAZSpoBtZV6J02gkNEyqIuZJLYnldvUQ73bwLrxG2oaKK6ErVzDMnuZMWMEzgNfGhIU4V6ONaw8YPtOOx-kVrMmEyNdEaJlmjQB9G2UUm27hT6ls01CgRCbLTCXAbM7iN-ZfbFGh_bWYzjNqlAXSpJcTspCrQ-_EyjLf4EcV2Yb5axrKdsoQYk4oCvcpeMfaEaiaYZtBDueUvW13dvtLNfidOb64iM58s0MHoWfeq4FNyuntEzOnRz2lqvfkf-tpDjwEqqpyztI92-stVeAtwrHfv0si7BShZMcM priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEF_qFdQX8bNGq6zYF4XYZLPJZgURW1pK4Q5RC30L-xU9SZPzLof63zuz-dDDck9ZkoFsMrM7v52d_Q0hB9qUSamVDiOtIgzd6FACzIeW4y7LmBT-FP90lp1d8PPL9HKHzIazMJhWOcyJfqK2jcEY-SF4filgPRUl7xc_QqwahburQwkN1ZdWsO88xdgNssuQGWtCdo9OZh8_jVEXpBfPfNlWhmeoU0BHI2cpO_xuVldvYsawcvE_XsqT-V-HQP9PpLy1rhfq909VVZtg13ur07vkTg8z6YfOLu6RHVffJzen_Ub6A-KmXSKhahG0UmisrhQtfYwPQ32YDE3nNTVoFEu4gG5_zdVbquhiXjUtbfQYzoX3qNrSFr1eNdzxtLUPycXpyZfjs7CvuBCalMM6MhcKljTGmDKVtjRGRIJZI2PLchcrLQ2AtdzJUtgki7XUmYSJFsR0nIpIpTZ5RCZ1U7vHhCqXsDySSW654VqkWijANi61kXFlpPOAvBr-cGF6OnKsilEVHZEyK1AbhddGQF6OsouOhONaqSNU1CiBxNn-RrP8WvTjsBDwMTrRXIBj5iXYosqZiqxOM23iLOIB2R_UXPSjeVX8tb2AvBgfwzjEzRVVu2a9wnKeIoa1J8sCstdZxdgTJnnGJYceig172ejq5pN6_s1zfac5MvaJgByMlrX1F7z2RrdFpDg__jz1rSfbP_UpuQ3gMO-ylPbJpF2u3TMAYK1-3o-qPzwjMIg priority: 102 providerName: ProQuest – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZQJwEv3C-BgYzYC0jtHMdX3sbENE3qhASVxlNkOw4UsqRqU3H59Rw7abTCNCHxVCs5aWznHJ_Px_Z3ENqzrsxKa-yYWENC6MaONcB8KHnmhaBaxlP801NxPGMnZ_zswin-jh9iCLgFy4jjdTDwRVF243y_uk_3v7rV-SSlVMKkfUdwQOMjtDM7fX_wKeSUC6ekuY5J82IZfLseGEovPrzlkyJ1_2V48-9tkzfW9cL8_G6qahvaRt90dBuZTau6LSnfJuvWTtyvPwgf_6fZd9CtHrjig07T7qJrvr6Hrk_7pfn7yE-7rYmmDTAYQ2F1bnAZo4YheBi2V-N5jV1QsyX8gLb8mJs32ODFvGpa3NghQAzvMXWB2-BHq82VSIT7AM2O3n08PB73ORzGjjOYmSppYJLknCu5LkrnJJG0cDotqPKpsdoB_FNel7LIRGq1FRqGbhCzKZfE8CJ7iEZ1U_vHCBufUUV0pgrmmJXcSgNoyfOCOF8SqxL0avMVc9cTnIc8G1XeUTPTPPRbHvstQS8H2UVH63Gp1NugDINEoOKOF5rl57y37FxCY2xmmQRXz0rQbqOoIYXlwrpUEJag3Y0q5f34sMoBx2qZZYpkCXox3AbLDss1pvbNehUShMoUZrNUJOhRp3lDTahmgmkGNZRbOrlV1e079fxLZA_nKnAAygTtDdp7ZRe8jtp4hUh-cvhhGktP_u0_n6KbADtVt_9pF43a5do_A2jX2ue99f4GS3hPMA priority: 102 providerName: Unpaywall – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9UwFA9jgvoifludEnEvCtelaT4a8UWHYwyuCDrYW8lJU73S9V5ue9n87z1JezuKY-BTQ3pK055zkt85SX4hZB9clVVgYcbAspC6gZlBmI8lL7xS3Oi4i3_-VR2fipMzebZDPm73wvT8EGPCLXhG7K-Dg1toD65IQ3-79vx9yrnGgP1WikAm2DcX38YMS6ASV_GIVh72S0tEQiM_KT-4enwyIkXi_uvQ5r-LJu9smpX9c2Hregps48h0dJ_cGyAl_dTbwAOy45uH5PZ8mDR_RPy8XzRouwBQKRbac0urmM8Lab2w8JkuGuqCAazxgnq8XNgP1NLVol52dAlj6hbfY5uSdmGEq7c1kaL2MTk9-vLj8Hg2nK4wc1JgzJhri-GLc66Spqyc00zz0pm05LlPLRiHwCz3ptJlplIwoAx2qigGqdTMyjJ7QnabZeOfEWp9xnNmsrwUToCWoC3iGC9L5nzFIE_I2-0fLtxAPR5OwKiLnjSZF0EbRdRGQt6MsquecONaqc9BUaNEIMmOFcv1z2LwuULjx0AGQuMgLCq0O5tzy0qQClyqmEjI3lbNxeC5bYEI02iM21mWkNfjbfS5MJFiG7_ctOHoTp1inMlVQp72VjG2hBuhhBHYQj2xl0lTp3eaxa_I6y3zwM6nE7I_WtaNv-BdNLobRIqTw-_zWHr-P8IvyF2EhXm_PmmP7HbrjX-J0KuDV9HD_gI18ist priority: 102 providerName: Wiley-Blackwell |
| Title | Multiplatform plasma fingerprinting in cancer cachexia: a pilot observational and translational study |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcsm.12270 https://www.ncbi.nlm.nih.gov/pubmed/29464940 https://www.proquest.com/docview/2329733803 https://www.proquest.com/docview/2007116426 https://pubmed.ncbi.nlm.nih.gov/PMC5879957 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/jcsm.12270 https://doaj.org/article/791db3b470124f629a82a0db56bc1604 |
| UnpaywallVersion | publishedVersion |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: KQ8 dateStart: 20100101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: KQ8 dateStart: 20100901 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: DIK dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: GX1 dateStart: 20100101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: RPM dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 7X7 dateStart: 20100901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: BENPR dateStart: 20100901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2190-6009 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: M48 dateStart: 20100901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Open Access Hybrid - NESLI2 2011-2012 customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 40G dateStart: 20100101 isFulltext: true titleUrlDefault: http://link.springer.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: U2A dateStart: 20100901 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature – providerCode: PRVWIB databaseName: KBPluse Wiley Online Library: Open Access customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: AVUZU dateStart: 20100901 isFulltext: true titleUrlDefault: https://www.kbplus.ac.uk/kbplus7/publicExport/pkg/559 providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2190-6009 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000461650 issn: 2190-5991 databaseCode: 24P dateStart: 20100101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ta9swED76Alu_jL3XWxc8VgYbpJNlWbIGY7SlpRQSwrZA9slIsrxluE6aF9b--51kxywslH1JhCwSWXfyPXc6PwdwqE0RF1rpLtGKuNCN7kqE-diyzHJOpfBv8ff6_GLILkfJaAtWSezNAs43unauntRwVh7dXN9-xg3_qSEQ_fDLzK-OIkoFeTu97rqCUu7gtamusQ27aLSkq-rQa5C_f0gzHnFfv5W6l6nR7MuWvPTvX1wzV57VfxMU_Tej8v6ymqrb36os11GvN1vnD-FBgzfD41pBHsGWrR7DvV5zov4EbK_OKFQLh15DbMyvVFj4YJ-L-bms6HBchcZpxwy_UMg3Y_UxVOF0XE4W4US3cV38H1Xl4cKZv3LV4_lrn8Lw_Ozb6UW3Kb3QNQlDhzIVCn0bY0yRyLwwRhBBcyOjnKY2UloaRG2plYXIYx5pqbnEJy4O01EiiEry-BnsVJPK7kOobExTIuM0Z4ZpkWihEOTYJCfGFkSnAbxbrXBmGl5yVx6jzGpGZZo5aWReGgG8acdOazaOjaNOnKDaEY5B23dMZj-yZkNmAm9Gx5oJtNCsQKVUKVUk1wnXJuKEBXCwEnO20soM4acU6NSTOIDX7WXckO6URVV2spy7up4iQieU8gCe11rRzoRKxplkOEOxpi9rU12_Uo1_etLvJHXUfSKAw1az7lyC917p7hiSXZ5-7fnWi_-4l5ewh1AxrXOWDmBnMVvaVwjHFroD25QN8FOMRAd2T876gy8dH9ro-C2HfcP-4Pj7H1t7O6Q |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKK1EuiDeBAkaUA0jbJo4Tx0gVoqXV9rErBK3UW_Ar7aJtsmyyKv1z_DbGzgNWVHvrKVYyShx7bH8zHn-D0LpUWZhJIXu-FL513cgeB5gPJUNNHBPO3Cn-wTDun9CD0-h0Cf1uz8LYsMp2TnQTtS6U9ZFvwsrPGdhTfvhx8rNns0bZ3dU2hYZoUivoLUcx1hzsODRXl2DClVv7n6G_3xKyt3u80-81WQZ6KqJgOyVMAIxXSmUR15lSzGdEKx5okphASK4AoCSGZ0yHcSC5jDlMLiAmg4j5ItIhvPcWWqEh5WD8rWzvDr987bw8ls48dmliiT2zHQEa6zhSyeYPVV5sBITYTMn_rIouecB1iPf_wM3VWT4RV5diPJ4H12513LuH7jawFn-q9fA-WjL5A3R70GzcP0RmUAcuisqCZAyF8kLgzPkUrWvRBl_jUY6VVcIpXECXfo3EByzwZDQuKlzIzn0M3xG5xpVdZcftHUeT-wid3EjbP0bLeZGbpwgLE5LE52GiqaKSRZIJwFIm0r4ymS8TD71rWzhVDf25zcIxTmviZpLa3khdb3joTSc7qUk_rpXath3VSViibnejmJ6lzbhPGfyMDCVlAARoBrovEiJ8LaNYqiD2qYfW2m5Om9mjTP_quoded49h3NvNHJGbYlba9KEsAFuXxB56UmtFVxPCaUw5hRqyOX2Zq-r8k3x07rjFo8QyBDIPrXeatbAJ3julWyCSHux8G7jSs8W_-gqt9o8HR-nR_vDwOboDwDSpI6TW0HI1nZkXAP4q-bIZYRh9v-lB_Qcn8G2i |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGkAYviG8CA4wYDyCVJo4Tx0gIwUa1DzohwaS-ZbbjbEVdUtpUY_8afx13zgdUTH3bU6zklDi-n-2fz-c7Qra0ycNcK93ztfLRdKN7Emg-lCy3ccykcKf4h4fx7hHfH0WjNfK7PQuDbpXtmOgG6qw0aCPvw8wvBayn_LCfN24RX3cGH6Y_e5hBCnda23QaNUQO7MU5LN_m7_d2QNevGBt8_r6922syDPRMxGHdlAgFFN4Yk0cyy40RvmCZkUHGEhsoLQ2Qk8TKXGRhHGipYwkDC4jpIBK-irIQ3nuNXId6SXQnFCPR2XcwkHnsEsQyPK0dAQ_roqOy_g8zP3sbMIY5kv-ZD13agMu47v8umzcWxVRdnKvJZJlWu3lxcJvcaggt_Vgj8A5Zs8VdsjFstuzvETusXRZVhfSYQmF-pmjurIloVES3azouqEH4zeACKPo1Vu-ootPxpKxoqTvDMXxHFRmtcH6dtHdcgNz75OhKWv4BWS_Kwj4iVNmQJb4Mk4wbrkWkhQIWZaPMNzb3deKR120Lp6YJfI75NyZpHbKZpaiN1GnDIy872Wkd7uNSqU-oqE4CQ3S7G-XsJG16fCrgZ3SouQAKwHNAvUqY8jMdxdoEsc89stmqOW3GjXn6F-UeedE9hh6P2ziqsOVijolDRQCrXBZ75GGNiq4mTPKYSw41FEt4Warq8pNifOqiikcJxgYUHtnqkLWyCd440K0QSfe3vw1d6fHqX31ONqArp1_2Dg-ekJvASJPaNWqTrFezhX0KrK_Sz1z3ouT4qvvzHyoYazw |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZQJwEv3C-BgYzYC0jtHMdX3sbENE3qhASVxlNkOw4UsqRqU3H59Rw7abTCNCHxVCs5aWznHJ_Px_Z3ENqzrsxKa-yYWENC6MaONcB8KHnmhaBaxlP801NxPGMnZ_zswin-jh9iCLgFy4jjdTDwRVF243y_uk_3v7rV-SSlVMKkfUdwQOMjtDM7fX_wKeSUC6ekuY5J82IZfLseGEovPrzlkyJ1_2V48-9tkzfW9cL8_G6qahvaRt90dBuZTau6LSnfJuvWTtyvPwgf_6fZd9CtHrjig07T7qJrvr6Hrk_7pfn7yE-7rYmmDTAYQ2F1bnAZo4YheBi2V-N5jV1QsyX8gLb8mJs32ODFvGpa3NghQAzvMXWB2-BHq82VSIT7AM2O3n08PB73ORzGjjOYmSppYJLknCu5LkrnJJG0cDotqPKpsdoB_FNel7LIRGq1FRqGbhCzKZfE8CJ7iEZ1U_vHCBufUUV0pgrmmJXcSgNoyfOCOF8SqxL0avMVc9cTnIc8G1XeUTPTPPRbHvstQS8H2UVH63Gp1NugDINEoOKOF5rl57y37FxCY2xmmQRXz0rQbqOoIYXlwrpUEJag3Y0q5f34sMoBx2qZZYpkCXox3AbLDss1pvbNehUShMoUZrNUJOhRp3lDTahmgmkGNZRbOrlV1e079fxLZA_nKnAAygTtDdp7ZRe8jtp4hUh-cvhhGktP_u0_n6KbADtVt_9pF43a5do_A2jX2ue99f4GS3hPMA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multiplatform+plasma+fingerprinting+in+cancer+cachexia%3A+a+pilot+observational+and+translational+study&rft.jtitle=Journal+of+cachexia%2C+sarcopenia+and+muscle&rft.au=Cala%2C+M%C3%B3nica+Patricia&rft.au=Agull%C3%B3-Ortu%C3%B1o%2C+Mar%C3%ADa+Teresa&rft.au=Prieto-Garc%C3%ADa%2C+Elena&rft.au=Gonz%C3%A1lez-Riano%2C+Carolina&rft.date=2018-04-01&rft.issn=2190-6009&rft.eissn=2190-6009&rft.volume=9&rft.issue=2&rft.spage=348&rft_id=info:doi/10.1002%2Fjcsm.12270&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2190-5991&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2190-5991&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2190-5991&client=summon |